[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626551":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":38,"studyPopulation":11,"armGroups":39,"interventions":60,"overallOfficials":11,"centralContacts":69,"locations":75,"responsibleParty":90,"collaborators":11,"id":92,"slug":11,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":11,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":11,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",null,"From Day -1 up to Day 34",{"measure":14,"description":11,"timeFrame":15},"Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","From Day -1 up to Day 66",[17,20,22,25],{"measure":18,"description":11,"timeFrame":19},"Part A: Maximum Observed Plasma Concentration (Cmax) of VX-272","From Day 1 up to Day 34",{"measure":21,"description":11,"timeFrame":19},"Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) of VX-272",{"measure":23,"description":11,"timeFrame":24},"Part B: Maximum Observed Plasma Concentration (Cmax) of VX-272","From Day 1 up to Day 66",{"measure":26,"description":11,"timeFrame":24},"Part B: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) of VX-272",{"allocation":28,"interventionModel":29,"interventionModelDescription":11,"primaryPurpose":30,"observationalModel":11,"timePerspective":11,"maskingInfo":31},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":32,"maskingDescription":11,"whoMasked":33},"QUADRUPLE",[34,35,36,37],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in healthy participants. Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)",[40,46,52,56],{"label":41,"type":42,"description":43,"interventionNames":44},"Part A: Single Ascending Dose","EXPERIMENTAL","Participants will be randomized to receive a single dose of VX-272.",[45],"Drug: VX-272",{"label":47,"type":48,"description":49,"interventionNames":50},"Placebo: Part A","PLACEBO_COMPARATOR","Participants will be randomized to receive a single dose of placebo matched to VX-272.",[51],"Drug: Placebo",{"label":53,"type":42,"description":54,"interventionNames":55},"Part B: Multiple Ascending Dose","Participants will be randomized to receive multiple doses of VX-272.",[45],{"label":57,"type":48,"description":58,"interventionNames":59},"Placebo: Part B","Participants will be randomized to receive multiple doses of placebo matched to VX-272.",[51],[61,66],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":11},"DRUG","VX-272","Suspension for Oral Administration.",[41,53],{"type":62,"name":67,"description":64,"armGroupLabels":68,"otherNames":11},"Placebo",[47,57],[70],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[76],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":11},"Celerion - Tempe","RECRUITING","Tempe","Arizona","85283","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-111.90931,33.41477,{"lat":88,"lon":87},{"type":91,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626551",false,"NCT07437105","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg\u002Fm\\^2)\n* A total body weight of more than (\\>) 50 kg\n* Male and Female participants of non-childbearing potential\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":103,"type":104},128,"ESTIMATED","INTERVENTIONAL",[107],"PHASE1","The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.",[110],"Cystic Fibrosis","2026-03-25",{"date":113,"type":114},"2026-03-31","ACTUAL",{"date":116,"type":114},"2026-02-25",{"date":118,"type":104},"2027-03-23",{"name":5,"class":6},1]